glp 1 dos and don ts GLP-1 Medications Infographic Long-term Success of GLP-1s Hinges

Aphaia Pharma Headquarters: Switzerland Technology: oral glucose formulation Lead candidate: APH-012 As disruptions in the guts natural responses to food intake are linked to metabolic diseases, such as obesity, Swiss biotech company Aphaia Pharma has come up with a way to restore these said natural responses, different from conventional obesity therapies like GLP-1 agonists

H., et al

Each order of GLP-1/GIP Microdose includes three 2mL vials of GLP-1/GIP and, if clinically appropriate, an additive

By helping patients lose weight, Wegovy can also lower the risk of cardiovascular events like heart attack or heart disease

doi: 10.1007/BF01316798